GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » Market Cap

First Wave BioPharma (First Wave BioPharma) Market Cap : $5.55 Mil (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is First Wave BioPharma Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). First Wave BioPharma's share price for the quarter that ended in Dec. 2023 was $4.2. First Wave BioPharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 1.56 Mil. Therefore, First Wave BioPharma's market cap for the quarter that ended in Dec. 2023 was $6.56 Mil.

First Wave BioPharma's quarterly market cap declined from Jun. 2023 ($6.73 Mil) to Sep. 2023 ($3.90 Mil) but then increased from Sep. 2023 ($3.90 Mil) to Dec. 2023 ($6.56 Mil).

First Wave BioPharma's annual market cap declined from Dec. 2021 ($21.48 Mil) to Dec. 2022 ($6.10 Mil) but then increased from Dec. 2022 ($6.10 Mil) to Dec. 2023 ($6.56 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. First Wave BioPharma's Enterprise Value for Today is $2.66 Mil.


First Wave BioPharma Market Cap Historical Data

The historical data trend for First Wave BioPharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

First Wave BioPharma Market Cap Chart

First Wave BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.96 30.15 21.48 6.10 6.56

First Wave BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 4.15 6.73 3.90 6.56

Competitive Comparison of First Wave BioPharma's Market Cap

For the Biotechnology subindustry, First Wave BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Wave BioPharma's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Wave BioPharma's Market Cap distribution charts can be found below:

* The bar in red indicates where First Wave BioPharma's Market Cap falls into.



First Wave BioPharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

First Wave BioPharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$4.2*1.561
=$6.56

First Wave BioPharma's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$4.2*1.561
=$6.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


First Wave BioPharma  (NAS:FWBI) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


First Wave BioPharma Market Cap Related Terms

Thank you for viewing the detailed overview of First Wave BioPharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


First Wave BioPharma (First Wave BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Executives
James Sapirstein director, officer: President and CEO 1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano officer: Chief Financial Officer 271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman director 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell director C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm director 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes director 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington officer: CHIEF MEDICAL OFFICER 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman officer: CHIEF FINANCIAL OFFICER 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr. 10 percent owner C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor director, officer: President and CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc 10 percent owner PO BOX 2422, WESTPORT CT 06880

First Wave BioPharma (First Wave BioPharma) Headlines

From GuruFocus